HLTH5453 Module 5 policy position stress test example

Will It Survive Contact With the Rules? Stress-Testing a 340B Savings Reporting Proposal Against Payment Law and Enactment Authority

Student Name

American College of Education

HLTH5453: Health Policy Evaluation and Development

Module 5 Assignment

Instructor Name

November 29, 2027

The Original Position

The evaluation earlier in this course found that the 340B program reliably increases resources for participating hospitals but that there is no strong evidence those resources reach low-income patients, and that the program's lack of reporting prevents a direct test (Desai & McWilliams, 2018). The position developed from that finding has three parts. First, the Health Resources and Services Administration would require every participating hospital to report, each year, its estimated 340B savings, calculated as the difference between what it pays for 340B drugs and what it is paid for them. Second, hospitals would report how those savings were used, in defined categories such as charity care, services in underserved areas and general operations. Third, Medicare would reduce its payment for 340B drugs to any hospital that failed to report.

The position is attractive because it addresses the accountability gap without cutting eligibility or benefits for hospitals that comply. Before it is presented to a decision maker, it has to be tested against the rules it would operate within. Bardach and Patashnik (2020) describe legality and political acceptability as criteria that a policy option must pass, alongside effectiveness and equity, and a proposal that fails them will not survive however sound its purpose. A position that has not been tested against the rules is a wish; a position that has survived the test is a proposal.

Test One: Can the Administering Agency Require Reporting?

The first part of the position assigns the reporting requirement to the Health Resources and Services Administration. The agency administers the program, but its authority to issue binding rules is limited, and courts have constrained earlier attempts to regulate aspects of the program by rule. The statute defines who may participate and sets pricing and compliance obligations, including prohibitions on duplicate discounts and diversion, but it does not require covered entities to account for their savings. Federal auditors have already found that the agency's oversight is limited in the areas the statute does address (U.S. Government Accountability Office [GAO], 2018), and a new reporting mandate issued as guidance would carry little force.

Result: the position fails this test as written. A binding reporting requirement on how savings are used almost certainly requires Congress to amend the statute. The agency could still encourage voluntary reporting and build reporting templates, but it cannot compel it on its own authority.

Test Two: Can Medicare Payment Enforce It?

The third part of the position uses Medicare payment as the enforcement tool: hospitals that fail to report would receive a lower payment rate for 340B drugs. The recent history of 340B payment policy makes this test decisive. When the Centers for Medicare and Medicaid Services lowered what it paid hospitals for 340B-acquired drugs, hospitals challenged the cut, and the Supreme Court held unanimously that the agency could not vary payment rates for a group of hospitals in this way without first conducting the survey of hospital acquisition costs that Medicare law requires (American Hospital Association v. Becerra, 2022). A payment penalty for failing to report would face the same procedural requirement and the same litigation.

Result: the position fails this test as written. A payment-based enforcement mechanism would need either explicit statutory authorization or a lengthy and contestable rulemaking process built on acquisition cost data. A more durable enforcement tool, if Congress acts, would be to make reporting a condition of continued participation in the program, enforced by the administering agency through the same process it uses for other compliance failures.

Test Three: Medicaid and the Definition of Savings

The first part of the position defines savings as the difference between acquisition cost and payment. That definition interacts with Medicaid in a way the original position did not address. The statute prohibits duplicate discounts, meaning a manufacturer should not both sell a drug at the 340B price and pay a Medicaid rebate on the same drug. Hospitals handle this in different ways, some carving Medicaid patients out of 340B purchasing altogether, and the choice changes how much each hospital appears to save. A single national formula for savings would produce figures that are not comparable across hospitals unless it specifies how Medicaid claims are treated.

Result: the position passes with revision. The reporting requirement must define savings separately for Medicare, Medicaid and commercial payers and require hospitals to state whether they carve Medicaid out. The revision makes the reports more complex but also more useful, because it would show which payers are generating the program's value for each hospital.

Test Four: Political Acceptability

The last test asks whether those who must approve the change, and those who can block it, would accept it. Removing the Medicare payment penalty improves acceptability considerably, because hospitals' strongest objection to earlier reforms was the loss of revenue. A reporting requirement without cuts is harder to oppose publicly, though hospital associations are likely to argue that it is burdensome and could be used later to justify cuts. Manufacturers would support reporting. Community health centers, which already report extensively as federal grantees, would be largely unaffected if the requirement applied only to hospitals. Result: the revised position passes, conditional on a design that limits the reporting burden, for example by using categories that match what hospitals already report to the Internal Revenue Service on community benefit. Using existing categories also means the new figures could be compared with each hospital's community benefit reports from earlier years, giving policymakers an immediate view of whether 340B savings track with the charity care and community programs hospitals already describe.

The Revised Position

After the stress test, the position reads differently. Congress would amend the statute to require participating hospitals, but not federal grantees, to report annually their 340B savings, calculated separately by payer with Medicaid carve-out status disclosed, and the use of those savings in categories aligned with existing community benefit reporting. Reporting would be a condition of continued participation, enforced by the administering agency, rather than a Medicare payment penalty. In the interim, the agency would publish voluntary reporting templates so that hospitals wishing to demonstrate their use of savings could begin immediately. The revised position asks for less than the original and is far more likely to become law, which is the purpose of testing it.

Conclusion

Stress-testing a 340B reporting proposal against payment law and enactment authority changed three of its features. The administering agency cannot compel reporting on its own, so the position now depends on Congress; Medicare payment cannot readily serve as the enforcement tool after the Supreme Court's decision, so enforcement now rests on program participation; and the definition of savings must account for Medicaid to produce comparable figures. The revised position keeps the original purpose, closing the accountability gap, while fitting within the rules it would have to operate under. The final module will compress it into a brief a decision maker could act on.

References

American Hospital Association v. Becerra, 596 U.S. 724 (2022).

Bardach, E., & Patashnik, E. M. (2020). A practical guide for policy analysis: The eightfold path to more effective problem solving (6th ed.). CQ Press.

Desai, S., & McWilliams, J. M. (2018). Consequences of the 340B drug pricing program. New England Journal of Medicine, 378(6), 539-548. https://doi.org/10.1056/NEJMsa1706475

U.S. Government Accountability Office. (2018). Drug discount program: Federal oversight of compliance at 340B contract pharmacies needs improvement (GAO-18-480).